Ognomy Sleep wants your diagnosis off the waiting list

The first obstacle to a good night’s sleep can arrive in broad daylight. It is an appointment calendar. Daniel Rifkin, a Buffalo sleep physician, describes patients waiting three, six, even nine months to see a specialist. They wanted an answer to their exhaustion. The system offered them a date.

Ognomy Sleep grew out of that mismatch. Its proposition is pleasantly unglamorous: connect the clinician, the home sleep test, the treatment discussion and the follow-up. A patient should have fewer loose ends to chase while already feeling tired.

The appointment before the appointment

Rifkin’s origin story begins with familiarity. After years in sleep medicine, he could see the awkward choreography around diagnosis: scheduling, travel, testing, results, another appointment. His company’s about page recounts 28 years of listening to patients. The opportunity was sitting in the gaps between perfectly respectable medical services.

“I’m a doctor and I knew I could help more patients by reinventing how they receive and experience sleep apnea care.”Daniel Rifkin, founder and CEO

There is a useful wrinkle in the dates. Later financing announcements place Ognomy’s founding in 2021. Topcoder, which helped build the original software, documents an early app launch in April 2020. The prototype and the operating company have different birthdays.

With Sam Marrazzo at Buffalo Niagara Medical Campus, the team spent two days turning ideas into storyboards. Topcoder then helped with interface design, software, payment and video integrations, and quality assurance. The early application arrived roughly four months after development began. The sequence is instructive: draw the actual patient journey, then build the machinery that carries it.

A sleep study with your own pillow

Start with someone concerned about snoring, interrupted breathing or daytime tiredness. Ognomy lets that person register online and meet a sleep clinician remotely. Lilly’s independent-care listing puts the first appointment within a week, on average. The consultation determines whether a home test makes sense.

If it does, a diagnostic device is shipped to the patient. The test gathers overnight information; a clinician interprets the results and discusses the next steps. Your bed supplies the setting. The service supplies the route from a question to a medical decision.

This puts Ognomy in a particular corner of digital health. A sleep tracker supplies observations. A device seller supplies equipment. Ognomy sells access to clinical care and coordinates what follows. Local sleep practices and hospital laboratories remain alternatives, particularly when the patient needs services that a home pathway cannot provide.

The $320 question

Convenience becomes more interesting when somebody names a price. Ognomy’s current published self-pay package is $320, covering an initial consultation, a home test and a follow-up consultation. It charges $124 at scheduling, then four payments of $49 beginning when the test is issued. Additional follow-up appointments cost $99 each.

That buys the diagnostic pathway. Medication, equipment and other prescribed therapies may generate separate charges. Insurance is another route: the company accepts most major plans and Medicare, with benefits checked before the appointment. A virtual visit still lives in the world of deductibles and copays. The screen has not abolished the insurance card.

The business model follows the work: medical services paid through insurers or directly by patients. Referring practices can send patients into the network, and Ognomy markets that referral service at no cost to the practice. For a clinician facing a backlog, the attraction is an available pathway that returns results.

The company between the companies

Ognomy’s partnerships reveal where it fits. In 2022, Inspire Medical Systems supplied seed funding and described a planned pilot connecting Ognomy with its Advisor Care Program. Inspire had identified long sleep-study waits as a problem. A therapy business needs patients to reach a sound diagnosis before they can consider an appropriate treatment.

In February 2025, Ognomy announced access through LillyDirect. Lilly now lists it as an independent telehealth option for sleep apnea. Ognomy also participates in Resmed’s Pathway program. These relationships place the service near people already looking for help, rather than relying entirely on someone discovering a new app.

The treatment menu includes CPAP, oral appliances, lifestyle changes and, for suitable patients, medication or surgical referrals. Its weight-management offering discusses Zepbound for eligible adults with obesity and moderate-to-severe obstructive sleep apnea. An Inspire implant still requires a procedure. Calling the network virtual does not put an operating room in the phone.

Ognomy’s Oura integration adds patient-authorized wearable information to clinical care. Its OgnomyFit lifestyle program extends the interest in sleep and metabolic health. Together, these offerings suggest a company seeking repeated contact, beyond delivering a test result.

A bedroom still has clinical limits

In June 2026, Ognomy announced a $20 million Series A led by Catalyst Investors, with Blue Heron Capital and other backers. It reported more than 85,000 visits and operations across all 50 states. Visits count encounters, including return appointments; they should not be mistaken for unique patients.

Home testing also has boundaries. American Academy of Sleep Medicine guidance supports it for appropriate uncomplicated adults. A negative, inconclusive or technically inadequate home test can require laboratory testing. More complex conditions can call for an in-person pathway from the outset.

The copyable idea is operational: give each handoff an owner. Make the next appointment, test shipment and treatment discussion easier to complete. Ognomy’s story is compelling because it notices how much work medicine quietly assigns to the person least delighted to receive another task: the patient.